Picker International's Outlook magnetic resonance imaging (MRI) system cleared in US
This article was originally published in Clinica
Executive Summary
Picker International (US) has received US FDA clearance for its Outlook MRI system which it introduced at last year's Radiology Society of North America (RSNA) meeting (see Clinica No 634, p 18). The 0.23T system's open design offers "unprecedented patient accessibility", says Picker. It features phased-array head, body and surface coils. The faster shielded gradients with 12mT/m peak and 20mT/m/ms rise time allow fast spin echo, magnetisation transfer contrast and 2D and 3D time of flight MR angio.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.